Æterna Zentaris Q2 net loss decreases

Æterna Zentaris, a biopharmaceutical company, has reported that net loss for the second quarter ended June 30, 2010 was $4.45 million, or $0.06 per share, compared to a net loss of $13.08 million, or $0.24 per share, for the same period of 2009.

Total revenues for the second quarter of 2010 were $5.58 million, compared to $8.38 million for the second quarter of 2009.

Net loss for the first six months of 2010 was $10.33 million, or $0.15 per share, compared to a net loss of $25.47 million, or $0.48 per share, for the first six months of 2009.

Total revenues for the first six months of 2010 were $12.01 million, compared to $14.49 million for the first six months of 2009.